Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials 2023

Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials 2023

Chronic Inflammatory Demyelinating Polyneuropathy research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in chronic inflammatory demyelinating polyneuropathy clinical trials today.

Trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients

Trials for CIDP Patients

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to chronic inflammatory demyelinating polyneuropathy

What are the top hospitals conducting chronic inflammatory demyelinating polyneuropathy research?

When it comes to advancing medical research and finding innovative treatments for chronic inflammatory demyelinating polyneuropathy (CIDP), several leading hospitals are making significant contributions. In the bustling city of Los Angeles, the Keck School of Medicine at USC is currently conducting an active CIDP trial, marking their first recorded study on this condition in 2022. Similarly, the University of Colorado in Aurora has also initiated a CIDP trial in 2022, showcasing their commitment to exploring new avenues for treatment. Down in Augusta, Georgia, Augusta University joins the effort by engaging in an active CIDP trial as well.

Moving towards Kansas City's medical scene where The University of Kansas Medical Center stands tall with its ongoing research efforts. They have one active clinical trial targeting CIDP and have been pioneers since 2015 when they launched their inaugural investigation into this condition.

Lastly but certainly not least is The Neurological Institute of New york located within the vibrant city itself which too acknowledges significance of progressing understanding towards Chronic Inflammatory Demyelinating Polyneuropathy through launching its very own cutting-edge trials from year 2022 onwards

Although there may only be one current study per hospital specifically focused on CIDP at present time as listed above; collectively these institutions demonstrate unwavering dedication to unravel mysteries surrounding this rare neurological disorder. Every small step taken is instrumental towards unlocking new knowledge that will ultimately improve lives impacted by chronic inflammatory demyelinating polyneuropathy around the world

Which are the best cities for chronic inflammatory demyelinating polyneuropathy clinical trials?

When it comes to clinical trials for chronic inflammatory demyelinating polyneuropathy (CIDP), several cities stand out as hubs of research and development. Tampa, Florida leads the way with 5 active trials focusing on treatments like SOC-Refractory Initial Dose and Efgartigimod PH20 SC. Following closely behind are Los Angeles, California; Kansas City, Kansas; New york, New York; and Orange, California, each hosting 3 active CIDP trials investigating potential breakthroughs such as Nipocalimab. These cities provide individuals with CIDP the opportunity to access cutting-edge clinical trials that may contribute to advancements in treatment options for this challenging condition.

Which are the top treatments for chronic inflammatory demyelinating polyneuropathy being explored in clinical trials?

Clinical trials for chronic inflammatory demyelinating polyneuropathy (CIDP) are exploring the potential of two promising treatments. Nipocalimab, introduced in 2022, is currently being tested in one active trial exclusively focused on CIDP. Similarly, efgartigimod PH20 SC, listed in 2020, is also undergoing evaluation through one ongoing clinical trial dedicated to CIDP. These treatments hold great promise and may pave the way for improved management of this debilitating condition.

What are the most recent clinical trials for chronic inflammatory demyelinating polyneuropathy?

Exciting advancements in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) have emerged from recent clinical trials. One such trial investigates the efficacy of nipocalimab, a potential breakthrough therapy for CIDP patients. The study involves both Phase 2 and Phase 3 stages, indicating its advanced progress in development since becoming available on September 23, 2022. Another notable trial focuses on SOC-Refractory Initial Dose as a therapeutic option specifically for individuals with CIDP who do not respond to standard-of-care treatments. This Phase 2 trial became accessible on April 28, 2021. Furthermore, efgartigimod PH20 SC offers hope as an investigational treatment for CIDP patients through its ongoing Phase 2 trials—the availability dates for this promising therapy are from September 18, 2020 onwards. These innovative clinical trials provide optimism and potential new avenues to enhance the lives of those affected by CIDP.

What chronic inflammatory demyelinating polyneuropathy clinical trials were recently completed?

Recently, several clinical trials investigating potential treatments for chronic inflammatory demyelinating polyneuropathy (CIDP) have reached completion. In April 2020, argenx completed a trial focusing on efgartigimod PH20 SC in stage B of CIDP. Additionally, two trials evaluating HYQVIA as a treatment for CIDP were wrapped up: one sponsored by Baxalta (now part of Shire) concluded in December 2016, and another trial by the same sponsor finished in December 2015. These noteworthy efforts contribute to advancing our understanding and management of this challenging neurological disorder.